Celgene Corp.

Pharmaceuticals
United States
Earnings Per Share Growth (%)-18.83%
Cost of Goods Sold (US$ Millions)$420
Current Liabilities (US$ Millions)$1,969
Total Assets (US$ Millions)$9,401
Long Term Debt$14,250
Return on Equity24.55%
Revenue (US$ Millions)$9,256
Total Company Assets$27,053
Revenue Growth (%)20.67%
Net Income (US$ Millions)$1,602
Earnings Per Share (US$)($18.83)
Total Equity (US$ Millions)$5,919
Profit Margin (%)17.31%
Debt To Equity Ratio (%)2.41%
Inventory Turnover$443